Replies to post #26331 on Intellipharmaceutics International Inc. (IPCI)

[wimuskyfisherman]

Tek- Does Seroquel approval and commercialization solve the cash problem? I think so... There may be a little gap until they get the first check but I am pretty confident they will be getting about $1M or a little more in Seroquel revenues per month. With Seroquel at $3M per quarter and Focalin at $1.5M per quarter we have $4.5M per quarter. Current burn rate is $3.25-3.5M per quarter. There might be a month or two until checks start rolling in that they are very tight. The ATM might be able to be the stop gap for that period. I guess we will have to wait and see. Everyone should research P/E. The standard P/E for IPCI sector is 50-60. The forward P/E for IPCI sector is 20-30. Should be an interesting year. Especially if Pristiq and/or Lamictal get approved. I think soon the cash flow problem will be behind IPCI. When no risk of dilution, what will bears complain about? I am sure the same old same old like management, transparency and especially the Purdue lawsuit. The big complaint will be that the future of Rexista is in jeopardy because of lawsuit...